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ANNEX 
EU Drugs Strategy 2021-2025 
 
INTRODUCTION – Aim, foundations and approach 
 
1. The EU Drugs Strategy 2021-2025 (hereinafter referred to as ‘the Strategy’) provides the 
overarching political framework and priorities for the European Union’s drugs policy for the 
period 2021-2025. The framework, aim and objectives of this Strategy will serve as the basis for 
the EU Action Plan on Drugs from 2021 to 2025. 
 
2. The Strategy aims to protect and improve the well-being of society and of the individual, to 
protect and promote public health, to offer a high level of security and well-being for the general 
public and to increase health literacy. The Strategy takes an evidence-based, integrated, balanced 
and multidisciplinary approach to the drugs phenomenon at national, EU and international level. 
It also incorporates a gender equality and health equity perspective. 
 
3. By 2025, the priorities and actions in the field of illicit drugs, coordinated through the Strategy, 
should have had an overall impact on key aspects of the EU drug situation. The coherent, 
effective and efficient implementation of measures should both ensure a high level of human 
health protection, social stability and security, and contribute to awareness raising. Any potential 
unintended negative consequences associated with the implementation of the actions should be 
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4. The Strategy is based first and foremost on the fundamental principles of EU law and, in every 
regard, upholds the founding values of the EU: respect for human dignity, liberty, democracy, 
equality, solidarity, the rule of law and human rights. The Strategy is also based on international 
law, the relevant United Nations (UN) Conventions1 which provide the international legal 
framework for addressing the illicit drugs phenomenon, and the Universal Declaration on Human 
Rights. The Strategy takes into account policy developments at multilateral level, and contributes 
to the acceleration of their implementation. First and foremost, the EU strongly supports the 
outcome document of the 2016 UN General Assembly Special Session (UNGASS) on the world 
drug problem entitled ‘Our joint commitment to effectively addressing and countering the world 
drug problem’, which is the most comprehensive policy document in that respect. It also 
supports the 2019 Ministerial declaration on strengthening our actions at the national, regional 
and international levels to accelerate the implementation of our joint commitments to address 
and counter the world drug problem, the applicable goals of the 2030 Agenda for Sustainable 
Development, the UN system common position supporting the implementation of the 
international drug control policy through effective inter-agency collaboration, and the 
International Guidelines on Human Rights and Drug Policy. The Strategy has been drafted on the 
basis of the principles set out in the Lisbon Treaty and taking into account the respective 
competences of the EU and individual Member States. Due regard is given to subsidiarity and 
proportionality, as the Strategy intends to add value to national strategies while respecting 
national needs and legislation. The Strategy should be implemented in accordance with these 
principles and competencies. Furthermore, the Strategy fully respects the European Convention 
on Human Rights and the Charter of Fundamental Rights of the EU and is guided by the human 
right to health, which should apply to everyone regardless of, for example, age or gender. All 
women, men and children, including people with drug-use disorders, have the right to enjoy the 
highest attainable standard of physical and mental health, including freedom from violence. 
 
                                                 
1 The 1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, the 1971 
Convention on Psychotropic Substances and the 1988 United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances. 
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5. Drug policy is of a cross-cutting nature. It is also a national and international issue that needs to 
be addressed in a global context, by a variety of stakeholders. The Strategy provides a common 
and evidence-based framework for responding in a consistent manner to the drugs phenomenon, 
within and outside the EU. It supports and complements national policies, provides a framework 
for coordinated and joint action and forms the basis and political framework for EU external 
cooperation in this field. It thereby ensures that resources invested in this area are used 
effectively and efficiently. 
 
6. The Strategy builds on valuable input from the Commission Communication EU Agenda and 
Action Plan on Drugs 2021-20252, on the lessons learned from the implementation of previous 
EU drugs strategies and action plans, including the findings from external evaluation3 and builds 
upon the EU’s achievements in this area. It also takes into account the EU Security Union 
Strategy for 2020-2025, the Health and Food Safety strategic plan for 2016-2020, and other 
relevant policy developments and actions at EU and international level in the field of drugs. In 
addition, the Strategy is informed by an ongoing assessment of the current drug situation, in 
particular as provided by the European Monitoring Centre for Drugs and Drug Addictions 
(EMCDDA) and Europol. Finally, it takes into account information provided by civil society. 
 
7. The Strategy addresses existing and evolving challenges, and takes on board evolving evidence-
based approaches. Furthermore, given the dynamic and complex nature of the drugs 
phenomenon, which once again became evident during the COVID-19 pandemic, the Strategy 
adopts a future-oriented approach in order to anticipate changes. Strategic foresight has been 
integrated with the intention to increase EU preparedness and ensure an efficient response to 
future challenges. 
 
                                                 
2  Communication from the Commission to the European Parliament, the Council, the 
European Economic and Social Committee and the Committee of the Regions, EU Agenda 
and Action Plan on Drugs 2021-2025. 
3 Commission Staff Working Document: Evaluation of the EU Drugs Strategy 2013-2020 and 
EU Action Plan on Drugs 2017-2020, July 2020, SWD(2020) 150. 
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8. The Strategy is structured around three policy areas that will all contribute to achieving its aim: 
(I.) Drug supply reduction: Enhancing Security, (II.) Drug demand reduction: prevention, 
treatment and care services, and (III.) Addressing drug-related harm; and three cross-cutting 
themes in support of the policy areas: (IV.) International cooperation, (V.) Research, innovation 
and foresight; and (VI.) Coordination, governance and implementation. Altogether, the Strategy 
encompasses 11 strategic priorities. 
 
I. DRUG SUPPLY REDUCTION: ENHANCING SECURITY 
Drug supply reduction includes the prevention of, dissuasion from and disruption of drug-related 
crime, in particular organised crime, through judicial and law enforcement cooperation, 
intelligence, interdiction, confiscation of criminal assets, investigations and border management. 
In the field of drug supply reduction, the objective of the Strategy is to respond, through an 
evidence-based approach, to the challenging development of European drug markets, which is 
characterised by a high availability of various types of drugs, ever larger seizures, increasing use of 
violence and huge profits. The Strategy therefore aims to contribute to the disruption of traditional 
and online illicit drug markets, the dismantling of organised crime groups that are involved in drug 
production and trafficking, efficient use of the criminal justice system, effective intelligence-led law 
enforcement, a reduction in the levels of violence associated with the illicit drug markets, and 
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Strategic priority 1: Disrupt and dismantle high-risk drug-related organised crime groups 
operating in, originating in or targeting the EU Member States; address links with other security 
threats and improve crime prevention 
Priority areas to address: 
1.1. Target high-risk organised crime groups active across the EU and cross-border 
drug markets; set priorities in synergy with the EU policy cycle for organised and 
serious international crime (EMPACT)4; disrupt criminal business models 
especially those that foster collaboration between different organised crime groups; 
and address links with other security threats. 
1.2. Track, trace, freeze and confiscate the proceeds of and instruments used by 
organised crime groups involved in the illicit drug markets. 
1.3. Prevent drug related crime with particular focus on the need to counter violence, 
limit corruption and address the exploitation of vulnerable groups by addressing the 
underlying factors that lead to their involvement in illicit drug markets.  
 
 
                                                 
4  https://www.europol.europa.eu/empact.  
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The following priorities have been identified: 
1.1. High-risk drug-related organised crime groups should be disrupted. Both operations that are 
large scale in terms of the volume of drugs or profits and those that are smaller scale but 
particularly harmful due to the nature of drugs concerned, such as new psychoactive 
substances (NPS), synthetic opioids, heroin, cocaine and methamphetamine, should be a 
priority target at EU level. In order to ensure efficiency and an evidence-based approach, this 
should be prioritised in synergy with the EU policy cycle for organised and serious 
international crime (EMPACT) that identifies, prioritises and addresses threats on a 
commodity-based approach. Furthermore, both top-level and established mid-level targets 
important for sustaining the operational continuity of organised crime groups should be a 
priority in order to disrupt their command structure. All actors in the chain who are 
experienced enough to provide continuity of criminal operations should be targeted. Links 
between drug-related criminality and other forms of serious crime need to be addressed.  
 
1.2. Focus should be given to tracking, tracing, freezing and confiscating the huge criminal assets 
obtained from drug trafficking and related offences in order to remove organised crime 
groups’ capacity to engage in future crimes and to infiltrate the legal economy. To effectively 
tackle drug trafficking, we must ensure that illegal profits do not go back into the illicit drug 
supply chain and do not enable criminal behaviour such as corruption and violence, or other 
forms of serious and organised crime, such as trafficking in human beings or even terrorism. 
Furthermore, measures to limit the criminal use of instruments that facilitate the illicit drug 
trade, such as equipment in drug laboratories used for the purposes of illicit drug production, 
firearms, falsified documents and encryption technology, should also be considered. Finally, 
seized and confiscated instruments and the proceeds from offences related to drugs could be 
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1.3. It is important to recognise the impact of drug-related crime, in particular on communities, 
and to counter the threats posed by these crimes, such as violence and intimidation, corruption 
and money laundering, and their associated negative effect on the legal economy. It is also 
necessary to counter the exploitation by organised crime groups of vulnerable groups, 
including children and young people and those with drug problems, by taking a 
multidisciplinary approach to the underlying factors which lead to their involvement in illicit 
drug markets. Countering and preventing these threats and promoting sustainable 
development is a significant challenge that requires concerted action at EU level and across a 
number of sectors.  
 
Strategic priority 2: Increase the detection of illicit wholesale trafficking of drugs and drug 
precursors at EU points of entry and exit  
Priority areas to address: 
2.1. Counter the smuggling of drugs and drug precursors in and out of the EU by using 
established legitimate trade channels. 
2.2. Increase monitoring of border crossings that are not part of established trade 
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The following priorities have been identified: 
2.1. Major known ports, airports and land entry and exit points in the EU that are used as hubs 
for the wholesale trafficking of drugs and drug precursors should be put on a high priority 
list for action targeting drug trafficking. Measures should include improved customs risk 
analysis of containers and cargo, profiling, intelligence sharing and effective cooperation 
across and between the competent EU agencies within their respective mandates and law 
enforcement, customs and border control agencies in Member States and relevant agencies 
of partner countries. Improved exchange of information and closer cooperation between 
customs and police authorities have been identified as critical in the fight against drug 
smuggling. Attention should also be given to further developing and extending anti-
corruption measures in relation to these hubs and to detecting any displacement effects 
resulting from effective interventions. 
 
2.2.It is important to monitor maritime, land and air borders to prevent illicit crossings relating 
to the drug trade. Within this scope, situational awareness activities should be reinforced for 
all EU external borders, including within Frontex in cooperation with Member States. 
Priority should be given to air and maritime borders due to their inherent vulnerabilities, the 
limited monitoring, and the strategic importance of the general aviation5 space, as well as 
the Atlantic Ocean and the Mediterranean Sea. During the COVID-19 pandemic, maritime 
shipping continued relatively unimpeded and trafficking opportunities remained available to 
organised crime groups involved in the wholesale transportation of drugs to Europe6. 
Activities such as those conducted by the Maritime Analysis and Operation Centre – 
Narcotics (MAOC (N)), e.g. monitoring vessels and aircrafts of interest carrying illicit drugs 
on the high seas and in the air space surrounding the known abused EU maritime borders 
and airspace with the aim of intercepting them before or when they reach their first EU port 
of entry, should be strengthened and extended. The general aviation space also poses a risk 
to the EU’s security and is increasingly used by drug traffickers, while remaining under-
monitored.  
                                                 
5  Aviation encompasses scheduled air transport, including passenger and cargo flights 
operating on regularly scheduled routes, and general aviation, which includes all other 
commercial and private civil flights. 
6  EMCDDA and Europol, EU Drug Markets – Impact of COVID-19, May 2020.   
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Strategic priority 3: Tackle the exploitation of logistical and digital channels for medium- and 
small-volume illicit drug distribution and increase seizures of illicit substances smuggled 
through these channels in close cooperation with the private sector  
Priority areas to address: 
3.1. Tackle digitally enabled illicit drug markets. 
3.2. Target drugs trafficking via postal and express services. 
3.3. Reinforce monitoring and investigation methods for cross-EU rail and fluvial 
channels and the general aviation space. 
 
The following priorities have been identified: 
3.1. Focus should be given to tackling the increased sales of illicit drugs, including NPS, via 
social media platforms, apps and internet/darknet market places, and the use of online 
payments (including cryptocurrencies) and encrypted digital communication. Engagement 
with the private sector should be enhanced in this regard.   
 
3.2. Trafficking of drugs via postal and express services should be targeted, also paying attention 
to the impact of the COVID-19 pandemic. In this context stricter monitoring of shipments 
containing illicit substances is needed in close cooperation with postal and express services. 
The role of new technologies and artificial intelligence in improving controls and procedures 
including the risk assessment of postal items7 can be examined, with the possibility of fully 
implementing advanced electronic data on all items that come from source countries 
(international and EU).  
 
                                                 
7  Postal item: an item addressed in the final form in which it is to be carried by a postal 
service provider. In addition to items of correspondence, such items also include, for 
instance, books, catalogues, newspapers, periodicals and postal parcels containing 
merchandise with or without commercial value. 
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3.3. Cross-border rail transport connections and fluvial channels and the general aviation space 
can be exploited as possible drug trafficking channels and are currently insufficiently 
monitored by law enforcement. Greater awareness is needed in order to reinforce  
monitoring and targeted risk-based investigations at smaller sea harbours and fluvial ports, 
small or local airfields and train stations.   
 
Strategic priority 4: Dismantle illicit drug production and counter illicit cultivation; prevent the 
diversion and trafficking of drug precursors for illicit drug production; and address 
environmental damage 
Priority areas to address: 
4.1. Counter illicit production of synthetic drugs and illicit cultivation of drugs. 
4.2. Tackle the diversion and trafficking of drug precursors and the development of 
alternative chemicals8.  
4.3. Address environmental crime related to illicit drug production and trafficking. 
 
The following priorities have been identified: 
4.1. Further efforts of law enforcement authorities are needed to detect and dismantle illicit 
synthetic drug laboratories and to stop exports of illicit drugs produced in the EU. Law 
enforcement authorities and other competent bodies should also strengthen measures to 
tackle illicit cultivation of drugs. 
 
4.2. Issues related to the diversion and trafficking of drug precursors and the development of 
alternative chemicals need to be addressed at European and international level.  
 
                                                 
8 The term alternative chemicals covers the wide range of substances variously referred to in 
both official and unofficial reports as ‘designer precursor’, ‘masked precursor’, ‘pre-
precursor’ or ‘masked drug’, EMCDDA, Drug Precursor Development in the European 
Union, 2019, page 2. 
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4.3. Environmental crime related to illicit drug production and trafficking needs to be targeted. 
As regards environmental damage, it is crucial to address the environmental impacts, 
hazards to health and costs associated with the chemical waste generated by illicit synthetic 
drug production, as also recognised in EMPACT. In this context, aspects related to the 
handling and destruction of seized illicit drugs, precursors and other chemicals and 
equipment used in illicit drug production, as well as the ecological disposal of the resulting 
waste should also be considered. 
 
II. DRUG DEMAND REDUCTION: PREVENTION, TREATMENT AND CARE 
SERVICES  
Drug demand reduction consists of a range of equally important and mutually reinforcing measures, 
including prevention (environmental, universal, selective and indicated), early detection and 
intervention, counselling, treatment, rehabilitation, social reintegration and recovery.  
In the area of drug demand reduction, the objective of the Strategy is to contribute to the healthy 
and safe development of children and young people and to a reduction of the use of illicit drugs. It 
also aims to delay the age of onset, to prevent and reduce problem drug use, to treat drug 
dependence, to provide for recovery and social reintegration through an integrated, 
multidisciplinary and evidence-based approach and by promoting and safeguarding coherence 
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Strategic priority 5: Prevent drug use and raise awareness of the adverse effects of drugs  
Priority areas to address: 
5.1. Provide, implement and, where needed, increase the availability of evidence-based 
environmental and universal prevention interventions and strategies for target 
groups and environments, in order to increase resilience and strengthen life skills 
and healthy life choices. 
5.2. Provide, implement and, where needed, increase the availability of evidence-based 
targeted prevention interventions for young people and other vulnerable groups. 
5.3. Provide, implement and, where needed, increase the availability of evidence-based 
early intervention measures.  
5.4. Disseminate the latest scientific evidence on prevention to decision makers and 
practitioners and provide them with training. 
5.5.   Address drug-impaired driving.  
 
The following priorities have been identified: 
5.1. The wide implementation of evidence-based environmental and universal prevention 
interventions and strategies, including those that build resilience, increase health literacy and 
promote life skills and opportunities to choose healthy lifestyles, is important for achieving 
health, welfare and well-being for all individuals. In addition, evidence-based programmes 
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5.2. Evidence-based measures should be available and implemented to support people 
experiencing particular and multiple disadvantages and who may be more vulnerable to the 
risks associated with drug use, including NPS use, and to developing risky drug-use 
patterns. Effective prevention should be appropriate to the local social context and to the 
needs of the target population, be informed by scientific evidence, and be safe and effective. 
In order to reach young people, full use should be made of new and innovative digital 
communication channels. The measures implemented should be evidence-based and should 
support positive relationships with peers and with adults. An important target group for 
prevention activities will be young people in multiple settings, including schools, families, 
night life, the workplace, the community and internet and social media. Special attention 
should also, however, be given to those groups that have been identified as particularly 
vulnerable to drug use in European, national and local research.   
 
5.3. Provide and, where needed, increase the availability of effective measures to prevent the 
development of severe drug-use disorders through appropriately targeted early interventions 
for people at risk of such progression, also by facilitating collaboration between all 
stakeholders, including parents and families, those working in education or family support, 
networks, youth services, student unions, sporting organisations and networks of people who 
use drugs. It is essential to make better use of primary healthcare professionals in order to 
improve the identification of problematic use and offer short early interventions. 
 
5.4. The European drug prevention quality standards (EDPQS), the UNODC/WHO 
International Standards on Drug Use Prevention and the European Prevention Curriculum 
(EUPC) compile the latest scientific evidence. It is important to disseminate these tools and 
advocate for evidence-based prevention and training among decision makers, opinion 
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5.5. Focus should be given to the prevention of drug-impaired driving and accidents caused by 
drug-impaired persons. In particular, awareness raising is required to highlight the risks of 
driving while impaired by drugs. This area requires further research and development to 
identify and evaluate effective policy and operational responses, including the development 
of more accessible roadside testing methods for drug detection.  
 
Strategic priority 6: Ensure access to and strengthen treatment and care services  
Priority areas to address: 
6.1. Ensure voluntary access to treatment and care services that work in close 
coordination and collaboration with other health and social support services. 
6.2. Promote peer work. 
6.3. Identify and remedy the barriers to accessing treatment and ensure and, where 
needed, extend coverage of treatment and care services based on individual needs.  
6.4. Reduce stigma. 
6.5. Widely implement treatment and care addressing the specific needs of women. 
6.6. Implement models of care that are appropriate for groups with special care needs. 
6.7. Provide and, where needed, improve access to, availability and appropriate use of 
substances for medical and scientific purposes. 
 
The following priorities have been identified: 
6.1. Ensure voluntary and non-discriminatory access to a broad range of effective evidence-
based services, including professional counselling, psychosocial, behavioural and 
medication-assisted treatment, including person-centred opioid maintenance therapy, 
rehabilitation, social reintegration and recovery support programmes. These services need to 
be well coordinated and need to work hand in hand with other social, health, employment 
and youth services in order to provide the full continuum of care and be both as effective as 
possible and focused on individual needs and existing comorbid disorders.  
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 Training for staff should be developed on the basis of evidence-based measures. Counselling 
and evidence-based treatment addressing poly drug use and the specific needs of young 
people who use drugs and their families should be implemented. 
 
6.2. Peer-led outreach and peer group work should be recognised as a key component of the care 
plan of a person who uses drugs, promoting autonomy, empowerment and recognising the 
peer’s expertise and experience. Peer-led work should be promoted as a way of sharing 
information, providing support and increasing awareness of relevant information among the 
community of people who use drugs. 
 
6.3. Barriers to accessing support services and treatment need to be addressed and it must be 
ensured that healthcare and social services are both sufficiently available, sufficiently 
funded and appropriate to the needs of their client groups, and that they take into account the 
gender perspective. This may also include e-health offers, especially in the context of the 
COVID-19 pandemic. Barriers to access should also be reduced with respect to the key 
characteristics of the target group, such as demographic factors (e.g. age, gender, education, 
cultural background), situational factors (e.g. poverty, family circumstances, social circle, 
homelessness, migration, imprisonment), and personal factors (e.g. physical and mental 
health, disabilities, psychological well-being).  
 
6.4. The stigmatisation linked to drug use and drug-use disorders needs to be addressed, 
especially as this stigma may have a detrimental effect on the mental and physical health of 
people who use drugs and could also act as a barrier to seeking support. In this regard, the 
inclusion of people that have experienced drug-related stigma should be particularly taken 
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6.5. Measures need to be taken to better identify and address the barriers that women face in 
engaging with and pursuing counselling, treatment and rehabilitation services. These 
barriers include domestic violence, trauma, stigma, physical and mental health issues, 
pregnancy and childcare issues, all of which may be aggravated by demographic, socio-
economic, situational and personal factors. Effective service delivery should be sensitive to 
the specific needs and life experiences of women with drug-use problems and should 
recognise that patterns of drug use and problems may differ from those experienced by men. 
Women-only service options should be developed, as should services that take care of 
accompanying children and that offer other forms of specialist care, such as close working 
partnerships with care providers and with services working with vulnerable women and 
victims of domestic violence.  
 
6.6. The diversity evident among people who use drugs should be recognised and steps should be 
taken to provide services that can address this diversity and reflect the needs of different 
groups in relation to problem drug use. Specific groups of people who use drugs and who 
have drug-use disorders that involve potentially more complex or specific care needs 
include: children and young people, older people with a history of long-term drug use and 
dependence, people with comorbid mental health problems, LGBTI, people with poly drug 
use, people who use drugs and are also parents, people with disabilities, ethnic minorities, 
migrants, refugees, asylum seekers, people who engage in sex work and prostitution and 
homeless people. Effective engagement with these groups also requires models of care that 
recognise the need for cross-service partnerships between healthcare, youth and social care 
providers, and patients/carers groups.  
 
6.7. The lack of access to and availability of controlled substances for medical and scientific 
purposes is a cause of unnecessary human suffering and not in line with international 
agreements and respect for human rights. At the same time, there is a real risk of misuse and 
diversion of these substances. The appropriate use of these substances is therefore 
imperative. A balanced approach that focuses both on the systemic, legal and financial 
issues and on the provision of capacity-building and awareness-raising activities needs to be 
promoted and implemented. 
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III. ADDRESSING DRUG-RELATED HARM 
The use of drugs may cause health and social harm to users but also to their family and the wider 
community. This chapter therefore focuses on measures and policies that prevent or reduce the 
possible health and social risks and harm for users, for society and in prison settings. National 
needs and national legislation must be taken into account when implementing these measures 
and policies. 
Prisoners are more likely to have used drugs compared with the general population, and they are 
also more likely to have engaged in risky forms of use, such as injecting drug use. Up to 70 % of 
European prisoners have used an illicit drug9. Drug problems can worsen in prison settings due 
to the difficulties in coping with incarceration and the availability of drugs, including NPS. At 
the same time, imprisonment can provide an opportunity for treatment and rehabilitation.  
 
Strategic priority 7: Risk- and harm-reduction interventions and other measures to protect and 
support people who use drugs  
Priority areas to address: 
7.1. Reduce the prevalence and incidence of drug-related infectious diseases and other 
negative health and social outcomes. 
7.2. Prevent overdoses and drug-related deaths. 
7.3. Promote civil society participation and ensure sustainable funding. 
7.4. Provide alternatives to coercive sanctions. 
 
                                                 
9  EMCDDA ‘Prison topics page’, https://www.emcdda.europa.eu/topics/prison_en. 
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The following priorities have been identified: 
7.1. The availability, accessibility and coverage of risk- and harm-reduction services need to be 
maintained and, where needed, improved. Training on evidence-based measures should also 
be implemented. These services should be guided by the minimum quality standards for 
drug demand reduction interventions in the EU. It is necessary to further prevent and treat 
blood-borne infectious diseases, especially HIV and Hepatitis C (HCV) and to reach high-
risk populations and put them in touch with care and other support services. Needle and 
syringe programmes, linked to low threshold social and health care services, opioid agonist 
treatment, accessible HIV and HCV voluntary testing and treatment interventions are 
implemented by EU Member States to prevent blood-borne infections among people who 
inject drugs. In addition, Member States have applied various innovative risk- and harm-
reduction measures to reach high-risk populations, e.g. supervised drug consumption 
facilities, to reduce risks and harm and put the most vulnerable groups in touch with care 
services. In addition, low threshold services, outreach work and co-operation with people 
who use drugs and their families are also essential for reducing the negative health and 
social impacts of drug use. 
 
7.2. Effective measures to prevent drug overdoses are missing from current responses. The use 
of the opioid antagonist naloxone, including take-home naloxone programmes, should 
therefore be further investigated and implemented as a way of responding to or intervening 
in opioid overdoses. In addition, further evidence is needed on supervised drug consumption 
facilities which aim to prevent drug-related deaths. Drug services also have an important 
role in preventing drug-related mortality. New measures should be considered. For example, 
innovative approaches should be developed and tested for people who use stimulant drugs 
and for young people who go to nightclubs and parties. In addition, the effective and 
positively evaluated innovations in harm-reduction services seen in some Member States as 
a result of the COVID-19 pandemic should be maintained. The monitoring and reporting of 
overdose deaths across the EU needs further improvement. Overdose deaths should be a key 
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7.3. To be most successful in reducing the risks and harm associated with the use of drugs, it is 
crucial to promote and encourage the active and meaningful participation and involvement 
of civil society, including non-governmental organisations, young people, people who use 
drugs, clients of drug-related services, the scientific community and other experts in the 
development and implementation of drug policies. It is also imperative that an appropriate 
level of resources be provided for all drug services at local, regional and national level.  
 
7.4. Although all Member States employ at least one alternative to coercive sanctions10, for drug-
using offenders and for people arrested, charged with or convicted for drug-related offences 
or people found in possession of drugs for personal use, stepping up efforts and 
mainstreaming the implementation of effective measures11 should be progressed. In this 
regard, drug consumption and/or drug possession for personal use or possession of small 
amounts do not constitute a criminal offence in many Member States, or there is the option 
to refrain from imposing criminal sanctions. More comprehensive and in-depth data and 
exchange of best practices between Member States is needed in this area.  
                                                 
10  The term "alternatives to coercive sanctions" can, according to the national legislation of the 
Member States, also refer to alternatives that are used instead of or in addition alongside the 
traditional criminal justice measures for drug-using offenders. 
11  Alternatives to coercive measures are defined as measures that have some rehabilitative 
element or that constitute a non-intervention (for example, deciding not to charge or 
prosecute), and those used instead of prison or other punishment (for example, a suspended 
sentence with drug treatment). See the Council conclusions of March 2018 on promoting the 
use of alternatives to coercive sanctions for drug using offenders (6931/18). 
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Strategic priority 8: Address the health and social needs of people who use drugs in prison settings 
and after release  
Priority areas to address: 
8.1. Assure equivalence and continuity of healthcare provision in prison and by 
probationary services. 
8.2. Implement evidence-based measures in prison settings to prevent and reduce drug 
use and its health consequences, including measures to address the risk of drug-
related deaths and the transmission of blood-borne viruses. 
8.3. Provide overdose prevention and referral services to ensure continuity of care on 
release. 
8.4. Restrict the availability of drugs in prisons. 
 
The following priorities have been identified: 
8.1. Drug treatment services, including opioid agonist treatment, rehabilitation and recovery for 
drug using offenders as well as provisions to reduce stigma need to be provided in male and 
female prisons and after release, in addition to supporting social reintegration. Developing a 
continuum of care model appropriate for each Member State and prison setting and 
probationary service is essential for allowing prisoners to access the range of support they 
need in order to achieve their personal recovery goals while entering prison and while in 
prison. Equally, after release prisoners should be supported by providing access to 
healthcare and social services, employment, housing and support for reintegration into 
society. It is essential to provide continued access to evidence-based drug services, 
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8.2. Preventing the use of drugs and the transmission of blood-borne infections within custodial 
settings through both evidence-based preventive measures and risk- and harm-reduction 
measures, implemented by well-trained staff or peers is part of a comprehensive strategy. 
Providing access to testing and treatment for blood-borne infections and other measures that 
reduce the health risks associated with drug use should be considered for prison settings in 
the same way as is done in the community.  
 
8.3. Upon release, overdose awareness trainings in combination with the distribution of take 
home naloxone might be made available where possible, in order to reduce overdoses and 
drug-related mortality. 
 
8.4. Disrupting the channels that supply illicit drugs and NPS into prisons should be a priority. 
Better use of the existing instruments such as cooperation with law enforcement agencies, 
sharing and processing information, tackling corruption, using intelligence and drug testing 





14178/20   MR/mdc 23 
ANNEX JAI.B  EN 
 
 IV. INTERNATIONAL COOPERATION  
Strategic priority 9: Strengthening international cooperation with third countries, regions, 
international and regional organisations, and at multilateral level to pursue the approach and 
objectives of the Strategy, including in the field of development. Enhancing the role of the EU as a 
global broker for a people-centred and human rights-oriented drug policy  
 
Due to the global nature of the drug phenomenon, the internal and external dimensions of the EU's 
drug policy are increasingly interconnected. International cooperation is therefore necessary to 
pursue the Strategy's approach and objectives. It should reflect the integrated, multidisciplinary, 
balanced and evidence-based EU approach outlined in the Strategy. It also contributes to the 
acceleration of the implementation of the commitments made by the EU at international level. The 
Sustainable Development Goals of the Agenda 2030 should guide the development of international 
drug policy. 
The EU's external relations in the field of drugs are based on the principles of shared responsibility, 
multilateralism, the promotion of a development-oriented approach, respect for human rights and 
human dignity, the rule of law and respect for the international drug control conventions.  
The acceleration of the implementation of the 2016 UNGASS Outcome Document and the 2030 
Agenda for Sustainable Development should be strongly supported. The UN system common 
position supporting the implementation of the international drug control policy through effective 
inter-agency collaboration, as well as the International Guidelines on Human Rights and Drug 
Policy, are important guidelines for international drug policy. Likewise, the continued involvement 
of civil society and the scientific community is of high importance to the EU, as they play a crucial 
role in assessing and addressing the world drug situation.  
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Furthermore, the integration of the Strategy and its objectives within the EU’s overall foreign policy 
framework as part of a comprehensive approach that makes full use of the variety of policies and 
diplomatic, political and financial instruments at the EU’s disposal in a coherent and coordinated 
manner should be guaranteed. This requires in particular that international cooperation in the field 
of drugs be integrated within the overall political relations and framework agreements between the 
EU and its partners, both at national and/or regional level. Where appropriate, and with a view to 
enhancing knowledge of the threat assessment, forms of cooperation with Common Security and 
Foreign Policy (CSFP) instruments (such as Common Security and Defence Policy (CSDP) 
missions and operations) should be used, within the framework of existing EU policies. The High 
Representative, supported by the European External Action Service (EEAS), should facilitate this 
process. 
 
Priority areas to address: 
9.1. Continue shaping the international and multilateral agendas on drug policy.  
9.2. Ensure a sustainable level of dialogue and information sharing on the strategies, 
aims and relevant initiatives with third countries or regions. 
9.3. Foster international cooperation by further involving competent EU agencies 
within their respective mandates. 
9.4. Continue, and establish new, cooperation programmes with third countries or 
regions and other partners based on regular evaluations of such programmes. 
9.5. Address all the policy aspects of the Strategy in international cooperation, 
including in the fields of security and judicial cooperation as well as the health-
related aspects of drugs issues. 
9.6. Strengthen the commitment to development-oriented drug policies and alternative 
development measures. 
9.7. Protect and promote adherence to international human right standards and 
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The following priorities have been identified: 
9.1. Shaping the international and multilateral agendas on drug policy in line with the Strategy's 
approach and objectives should be continued. This includes strategic cooperation with 
international organisations, in particular with UNODC as the leading entity within the UN 
system for addressing and countering the world drug situation, as well as the EU's 
participation in UN policy processes, in particular the Commission on Narcotic Drugs 
(CND) as the principal policymaking body of the UN with prime responsibility for drug 
control matters, as well as in other UN fora focusing on health, human rights and 
development.  
 
9.2. A sustainable level of policy dialogue and information sharing on the strategies, aims and 
relevant initiatives through the dialogues on drugs with international partners, both at 
regional and bilateral level, should be ensured. These forms of dialogue are a key element of 
the EU’s approach to international cooperation. Partners with which to continue or launch 
dialogues on drugs are identified on the basis of their relevance in addressing the global 
drug situation and taking into account the EU’s overall relations with those partners. These 
dialogues should be complementary to, and consistent with, other external cooperation 
structures and their impact and, where appropriate, should provide a forum for discussing 
cooperation priorities and progress on EU-funded projects. 
 
9.3. International cooperation in the field of drugs should be fostered by further involving EU 
agencies, especially Europol and the EMCDDA, within their respective mandates, in 
synergy with the work of international actors, and by providing them with the relevant 
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9.4. Cooperation initiatives and programmes are key to further strengthening and supporting 
third countries' efforts to address drug issues in an evidence-based, integrated, balanced and 
multidisciplinary manner and in full compliance with international human rights obligations. 
These include programmes aimed at addressing challenges in the fields of public health, 
development, safety and security. An appropriate level of funding and expertise (provided 
by the EU and its Member States), including by reinforcing coordination, monitoring and 
evaluation of financial and technical support, should be ensured.  
 
This should also include support for candidate and potential candidate countries, and the 
countries of the European Neighbourhood Policy, focusing on capacity-building on both 
supply and demand reduction and evidence-based, effective and balanced drug policies, 
through strengthened cooperation, including the sharing of EU best practices.  
 
9.5. International cooperation in the field of drugs should address the whole range of policy 
aspects of the Strategy, including the intertwined security-, development- and health-related 
aspects of the drugs issues. 
 
 This should include drug-related crime prevention, law enforcement and judicial 
cooperation, as well as addressing possible links to terrorism and other forms of 
transnational crime, as defined in the UN legal framework. Addressing the production of 
drugs in partner countries, in full compliance with international human rights obligations, 
contributes significantly to reducing the supply and availability of drugs on the domestic EU 
market. In promoting and supporting international judicial and law enforcement cooperation, 
as well as cooperation between drug observatories, and the capacity-building of relevant 
authorities, measures under this priority should continuously seek to address the root causes 
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 This should also include addressing health-related aspects of drug use, in particular the 
impact of demand and supply reduction interventions on people who use drugs and the 
public. This implies the promotion of prevention, treatment, risk and harm reduction and 
alternatives to coercive sanctions and social reintegration in line with human rights 
obligations. Furthermore, increased access to and availability of controlled substances for 
medical and scientific purposes should be promoted. 
 
9.6. The cultivation of illicit drugs in third countries with possible implications for the EU, in 
particular opium poppies for heroin production and coca plants for cocaine production as 
well as cannabis, should also be addressed by a renewed and strong commitment to 
alternative development measures12: tackling the root causes of illicit drug economies 
through an integrated approach combining efforts on rural development, poverty alleviation, 
socio-economic development, the promotion of access to land and land rights, 
environmental protection and climate change, the promotion of the rule of law, security and 
good governance, within the framework of the 2030 Agenda for Sustainable Development 
and in full compliance with international human rights obligations and a commitment to 
gender equality. These development cooperation efforts should adhere to the OECD-
Development Assistance Committee’s (DAC) guidelines and standards.  
 
 Those measures should also adhere to the principles of non-conditionality, non-
discrimination, and proper sequencing, while the success of these interventions should be 
measured using socio-economic indicators which go beyond an exclusive focus on illicit 
drug crop monitoring indicators, ensuring ownership among target communities. 
 
 This includes acknowledging development-centred drug policy interventions as a legitimate 
means of addressing phenomena such as drug trafficking and urban drug markets in 
developing countries. 
 
                                                 
12  See the Council conclusions of November 2018 on Alternative Development: “Towards a 
new understanding of Alternative Development and related development-centered drug 
policy interventions - contributing to the implementation of UNGASS 2016 and the UN 
Sustainable Development Goals” (14338/18). 
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9.7.The protection and promotion of human rights should be fully integrated into, and a specific 
objective of, the EU's external action on drugs issues, including engagement at multilateral 
level, political dialogues and the implementation and delivery of relevant programmes and 
projects in the field of drugs. This includes upholding the principle of an adequate, 
proportionate and effective response to drug-related offences, as highlighted in all UN 
documents on drug policy. The EU is strongly and unequivocally opposed to the use of the 
death penalty at all times and under all circumstances. Capital punishment violates the 
inalienable right to life and is incompatible with human dignity. It does not serve as a 
deterrent to crime and makes any miscarriage of justice irreversible. The application of the 
death penalty for drug-related offences also violates Article 6 of the International Covenant 
on Civil and Political Rights13. Human rights are universal, inalienable, indivisible, 
interdependent, and interrelated, including in the contexts of drug policy, development 
assistance, health care, and criminal justice14. 
 
                                                 
13 ‘In countries which have not abolished the death penalty, sentence of death may be imposed 
only for the most serious crimes’ which are ‘intentional crimes with lethal or other 
extremely grave consequences’. UN Economic and Social Council (ECOSOC) Resolution 
1984/50 of 25 May 1984. 
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V. RESEARCH, INNOVATION AND FORESIGHT  
 
Strategic priority 10: Building synergies to provide the EU and its Member States with the 
comprehensive research evidence base and foresight capacities necessary to enable a more 
effective, innovative and agile approach to the growing complexity of the drugs phenomenon, and to 
increase the preparedness of the EU and its Member States to respond to future challenges and 
crises  
The scope of the cross-cutting field of research, innovation and foresight covers both the health and 
security aspects of the drugs phenomenon, and recognises that they are intrinsically linked. Its 
objective is to contribute to a better understanding of all aspects of the drugs phenomenon and of 
what constitute effective interventions, so as to provide a sound evidence base for necessary policy 
development and practice. It will ensure that maximum value is derived from investment in this area 
by fostering synergies and the efficient allocation of resources. Furthermore, in recognition of the 
growing dynamism and complexity of the drugs phenomenon, it will encourage a future-oriented 
approach that allows new trends and developments to be more rapidly identified, and evidence-
based responses to be more rapidly put in place. This requires the development of the technological 
capacity necessary to allow the EU and its Member States to be better prepared to anticipate and 
respond to new challenges or future crises that have the potential to impact the drugs situation. 
 
Priority areas to address: 
10.1. Strengthen and broaden research capacities and encourage the greater sharing 
and use of results. 
10.2. Foster innovation, so that policy and actions shift from a reactive to a proactive 
mode.  
10.3. Develop strategic foresight and a future-oriented approach. 
10.4. Strengthen coordination and synergies, and support the central role of the 
EMCDDA, Europol and the Reitox network of national focal points in research, 
innovation and foresight.  
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The following priorities have been identified: 
10.1. It should be a priority to strengthen and broaden capacities in information gathering, 
monitoring, evaluations, modelling and analysis and to encourage the greater sharing and 
use of the results on the various aspects of the drug phenomenon and on responses. This 
should take into account the expertise of the scientific community and civil society. In this 
context, it is necessary to ensure consistency and coherence with similar initiatives at 
international level as well as efficiency and cost-effectiveness, and to avoid any 
unnecessary additional administrative burden, in particular related to data collection by the 
EMCDDA and UNODC.  
 
10.2. It is important to strengthen the capacity to respond proactively rather than reactively to 
new challenges and emerging threats by innovation and the development and use of new 
methods and technologies and opportunities for interventions arising from digitalisation. In 
particular, efforts should be intensified to develop, adopt and use early warning 
approaches, and forensic and new technologies, to better monitor, model, analyse and 
respond to new challenges and emerging threats to public health and security. There is a 
need for an improved and coordinated monitoring and analysis of the threats posed by 
digitalisation, in particular the accessibility of illicit drugs via social media platforms, apps, 
internet/darknet market places, as well as the use of online payments (including 
cryptocurrencies) and encrypted digital communication.   
 
10.3. There is a need to develop strategic foresight and a future-oriented approach to increase 
preparedness to identify and respond to potential future challenges, helping to create 
institutional resilience and fostering more agile responses. This should include research to 
better understand the links between the drugs phenomenon and other important policy 
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10.4. Research, innovation and foresight should result from the coordinated efforts of the various 
stakeholders at EU and national level, thus entailing synergies and complementarity to 
ensure that investment in research delivers maximum value. The Member States should 
increase and coordinate their efforts in data collection, monitoring, modelling and analysis, 
research, innovation and foresight on all relevant aspects of the drug phenomenon, 
including by further supporting the existing data collection and interface role of the Reitox 
network of national focal points. Within their respective mandates, the EMCDDA, Europol 
and the Reitox network of national focal points should have the means, including financial 
resources, to play their central supporting role in early warning, threat and risk assessment, 
research, innovation and foresight, in order to provide timely and sound evidence for 
policy makers and to support Member States in building their national policy and actions 
on evidence-based information. Based on the early signals identified, modelling and the 
analysis of current data and information, competent agencies, especially the EMCDDA and 
Europol within their respective mandates, should lead at European level scientific risk 
assessments and strategic and operational threat assessments to inform and stimulate 
research, innovation and foresight on both controlled illicit drugs and NPS. 
 
10.5. The EU and its Member States should ensure adequate financing for drug-related research, 
innovation and foresight in line with the implementation of the Strategy. This should 
include the use of the Internal Security Fund, the EU4Health programme, the security 
research part of Horizon Europe, Cohesion Policy Funds, the Digital Europe programme 
and the Rights and Values programme, in line with the requirements of the Strategy and 
the Action Plan to deliver clear EU added value, ensuring coherence and synergies while 
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VI. COORDINATION, GOVERNANCE AND IMPLEMENTATION  
Strategic priority 11: Ensuring optimal implementation of the Strategy and of the Action Plan, 
coordination by default of all stakeholders and the provision of adequate resources at EU and 
national levels  
 
1. On the basis of the Strategy the EU Action Plan on Drugs 2021 - 2025 (hereinafter referred to 




a) must be evidence-based, scientifically sound and aim for realistic and measurable 
results that can be evaluated; 
b) will be time-bound and will identify the parties responsible for their implementation; 
c) must have a clear EU relevance and added value. 
 
2. The implementation of the Strategy and of the Action Plan should facilitate synergies and 
consistency between policies on drugs at EU and national level. The Commission, taking into 
account information provided by the Member States and the EEAS, and available from the 
EMCDDA, Europol and other EU bodies, as well as from civil society, should monitor the 
implementation of the Strategy and the Action Plan. Close cooperation and coordination is 
essential in this area, given the intertwined competences at EU and national level. In order to 
facilitate coordination and allow any necessary policy follow-up, including monitoring, the 
Commission, the Presidency and the Horizontal Working Party on Drugs (HDG), as the 
Council preparatory body in charge of drug policy, will closely cooperate together. In 
addition, the HDG should hold discussions or exchanges of best practices which could 
provide support to the Member States in their implementation of the Strategy and of the 
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3. The Commission, taking into account information provided by the Member States and the 
EEAS, and available from the EMCDDA, Europol, other relevant EU institutions and bodies 
and civil society, is requested to initiate an overall external evaluation of the implementation 
of the Strategy and of the Action Plan. The results of this evaluation will be made available to 
the European Parliament and to the Council as soon as they are available, and at the latest by 
31 March 2025, in order to be discussed in the relevant fora and in particular in the HDG. 
These discussions will form the basis for the definition of the future development of EU drug 
policy and the following cycle of the EU Drugs Strategy to be approved by the Council. 
 
4. Appropriate and targeted resources should be allocated for the implementation of the 
objectives of this Strategy at both EU and national level. The allocation of resources should 
be directed proportionally towards those strategic priorities, areas and interventions that are 
most likely to achieve the aims of the Strategy and Action Plan at EU, national and local 
levels. Funding in support of the priorities set in the Strategy should be allocated from cross-
sectoral EU funding sources, including notably the Internal Security Fund, the EU4Health 
programme, the security research part of Horizon Europe, Cohesion Policy Funds, the Digital 
Europe programme and the Rights and Values programme. 
 
5. Following the evaluation of the EMCDDA, the Commission is invited to present a proposal to 
revise the mandate of the EMCDDA as soon as possible, to ensure that the agency plays a 
stronger part in addressing the current and future challenges of the drug phenomenon. 
Furthermore, the EMCDDA and Europol will need to be provided with the relevant resources 
to enable them to fulfil their roles in line with their respective mandates and the Strategy, 
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6. Coordination plays a crucial role in the efficiency of EU drug policy and of its 
implementation, especially given the cross-cutting nature of this field. To achieve the 
objectives of the Strategy, there should be coordination with agencies, bodies or organisations 
that have relevance for the drugs field, within their respective mandates: both within the EU - 
in particular the EMCDDA and Europol - and outside the EU, such as UNODC, WCO, WHO 
and the Pompidou Group. The EU institutions and the High Representative, each within the 
scope of their respective powers, should seek to ensure that the EU's activities in the field of 
illicit drugs are coordinated and that they complement each other. Where relevant, the EU 
should also promote coordination among external actors, including in the UN context. 
 
7. In the Council of the EU, the HDG, as the main coordinating body on drug policy, should be 
kept informed of possible work linked to drugs issues, carried out by other preparatory bodies 
of the Council, such as the Standing Committee on Operational Cooperation on Internal 
Security (COSI) and the Working Party on Public Health, as well as other relevant Council 
preparatory bodies, including in the area of customs, judicial and criminal matters, law 
enforcement, social affairs, agriculture and external relations. 
 
8. Coordination and synergies should be sought between the drug policy and the other policies, 
including in the security and health areas. Coordination should involve the relevant 
stakeholders in the various areas, including law enforcement, customs including customs 
laboratories, border control, the judiciary, prisons and correctional facilities, civil aviation and 
maritime authorities, medicines agencies, postal services, stakeholders involved in research, 
innovation and monitoring, including the Reitox network of national focal points, social and 
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9. Externally, the EU and its Member States should promote the approach and objectives of the 
Strategy with one voice. EU delegations should play a useful role in promoting this and in 
facilitating a coherent EU discourse on drug policy.  
 
10. The meaningful participation and involvement of civil society, including the Civil Society 
Forum on Drugs, should be ensured in the development and implementation of drug policies, 
at national, EU and international levels. 
 
  
 
